The report on the Global Liquid Biopsy Market gives an estimation of the development of the market based on historical studies and also provides forecasts on the basis of a comprehensive research. The report gives a complete market analysis for the forecasted period from 2020 to 2026. The market is divided into various segments with an in-depth outlook of the competitors and a listing of the profiled key players. The market size in terms of revenue (USD MN) is calculated and provided for the study period along with the dynamics of the market such as the drivers and the restraints.
Major Drivers
- Adoption of liquid biopsies
- Help in detection of cancer in its early stage
|
Major Restraints
- Dearth of skilled professionals
|
The comprehensive value chain analysis of the market will assist in attaining better product differentiation, along with detailed understanding of the core competency of each activity involved. The market attractiveness analysis provided in the report aptly measures the potential value of the market providing business strategists with the latest growth opportunities.
The report classifies the market into different segments based on approach of diagnosis, type of cancer application and channel participants. These segments are studied in detail incorporating the market estimates and forecasts at regional and country level. The segment analysis is useful in understanding the growth areas and probable opportunities of the market.
The report also covers the complete competitive landscape of the global Liquid Biopsy market with company profiles of key players such as:
- Janssen Diagnostics, LLC
- Qiagen
- Rarecells SAS
- Silicon Biosystems
- SRI International
- Myriad Genetics
- Natera Inc
- Personal Genome Diagnostics
- Sysmex Inostics
- Trovagene Inc.
- Exosome Diagnostics
- Exosome Sciences
- HansaBiomed OU
A detailed description of each has been included, with information in terms of H.Q, future capacities, key mergers & acquisitions, financial overview, partnerships, collaborations, new product launches, new product developments and other latest industrial developments.
SEGMENTATIONS IN THE REPORT:
By Approach of Diagnosis:
- Circulating Tumor Cells (CTC)
- Circulating Tumor DNA (ctDNA)
- RNA in Exosomes
- Extra-cellular Vesicles (EVs)
By Type of Cancer Application:
- Lung Cancer
- Pancreatic Cancer
- Leukemia (Blood Cancer)
- Other Visceral (Deeply Located) Cancers
By Channel Participants:
- Cancer Centers and Hospitals
- Contract Research Organizations
- Academic Institutions
- Specialized Research Laboratories
By Geography:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East And Africa
The Global Liquid Biopsy Market has been exhibited in detail in the following chapters -
Chapter 1 Liquid Biopsy Market Preface
Chapter 2 Executive Summary
Chapter 3 Liquid Biopsy Industry Analysis
Chapter 4 Liquid Biopsy Market Value Chain Analysis
Chapter 5 Liquid Biopsy Market Analysis By Approach of Diagnosis
Chapter 6 Liquid Biopsy Market Analysis By Type of Cancer Application
Chapter 7 Liquid Biopsy Market Analysis By Channel Participants
Chapter 8 Liquid Biopsy Market Analysis By Geography
Chapter 9 Competitive Landscape Of Liquid Biopsy Companies
Chapter 10 Company Profiles Of Liquid Biopsy Industry
METHODOLOGY:
A combination of primary and secondary research has been used to determine the market estimates and forecasts. Sources used for secondary research include (but not limited to) Paid Data Sources, Company Websites, Technical Journals, Annual Reports, SEC Filings and various other industry publications. Specific details on methodology used for this report can be provided on demand.